Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma

Authors :: Andrew Gnan
John M. Kirkwood
Yan Lin
Chelsea Pruckner
Uma N. M. Rao
Zahra Rahman
Amy Rose
James F. Pingpank
Melissa Wilson
Hussein Abdul-Hassan Tawbi
Robert L. Ferris
Priyanka Vallabhaneni
Matthew P. Holtzman
Amanda McFadden
Ahmad A. Tarhini
Source :: Journal of Clinical Oncology. 34:9585-9585
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 9585Background: Neoadjuvant ipilimumab (ipi) at 3 or 10 mg/kg in combination with high dose IFNα2b (HDI) for locally/regionally advanced or recurrent melanoma may improve the clinical outcomes of t...

Subjects :: 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Ipilimumab
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Recurrent Melanoma
hemic and lymphatic diseases
030220 oncology & carcinogenesis
Internal medicine
medicine
Combination immunotherapy
business
medicine.drug
Advanced melanoma

Tools